20 September 2023 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adults with previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency.

Pembrolizumab is recommended as an option for the treatment of adults with a high microsatellite instability or mismatch repair deficiency tumour with:

• Advanced or recurrent endometrial cancer that has progressed during or after a platinum-based therapy, who cannot have curative surgery or radiotherapy
• Unresectable or metastatic gastric, small intestine or biliary cancer that has progressed during or after one therapy
• Colorectal cancer after fluoropyrimidine combination therapy, only if they cannot have nivolumab with ipilimumab

Read NICE technology appraisal guidance